Mitchell LM - Search Results

1

A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.

Thurman JM, Kraus DM, Girardi G, Hourcade D, Kang HJ, Royer PA, Mitchell LM, Giclas PC, Salmon J, Gilkeson G, Holers VM. Thurman JM, et al. Among authors: mitchell lm. Mol Immunol. 2005 Jan;42(1):87-97. doi: 10.1016/j.molimm.2004.07.043. Mol Immunol. 2005. PMID: 15488947

2

A conserved element in the serine protease domain of complement factor B.

Hourcade DE, Mitchell LM, Oglesby TJ. Hourcade DE, et al. Among authors: mitchell lm. J Biol Chem. 1998 Oct 2;273(40):25996-6000. doi: 10.1074/jbc.273.40.25996. J Biol Chem. 1998. PMID: 9748277 Free article.

3

Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding.

Hourcade DE, Mitchell LM, Oglesby TJ. Hourcade DE, et al. Among authors: mitchell lm. J Immunol. 1999 Mar 1;162(5):2906-11. J Immunol. 1999. PMID: 10072540

4

Decay acceleration of the complement alternative pathway C3 convertase.

Hourcade DE, Mitchell LM, Medof ME. Hourcade DE, et al. Among authors: mitchell lm. Immunopharmacology. 1999 May;42(1-3):167-73. doi: 10.1016/s0162-3109(99)00005-3. Immunopharmacology. 1999. PMID: 10408377

5

Characterization of the active sites in decay-accelerating factor.

Kuttner-Kondo LA, Mitchell L, Hourcade DE, Medof ME. Kuttner-Kondo LA, et al. J Immunol. 2001 Aug 15;167(4):2164-71. doi: 10.4049/jimmunol.167.4.2164. J Immunol. 2001. PMID: 11490001

6

Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.

Hourcade DE, Mitchell L, Kuttner-Kondo LA, Atkinson JP, Medof ME. Hourcade DE, et al. J Biol Chem. 2002 Jan 11;277(2):1107-12. doi: 10.1074/jbc.M109322200. Epub 2001 Nov 2. J Biol Chem. 2002. PMID: 11694537 Free article.

7

A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases.

Kuttner-Kondo LA, Dybvig MP, Mitchell LM, Muqim N, Atkinson JP, Medof ME, Hourcade DE. Kuttner-Kondo LA, et al. Among authors: mitchell lm. J Biol Chem. 2003 Dec 26;278(52):52386-91. doi: 10.1074/jbc.M304620200. Epub 2003 Oct 15. J Biol Chem. 2003. PMID: 14561755 Free article.

8

Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly.

Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Spitzer D, et al. Among authors: mitchell lm. J Immunol. 2007 Aug 15;179(4):2600-8. doi: 10.4049/jimmunol.179.4.2600. J Immunol. 2007. PMID: 17675523

9

The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis.

Kemper C, Mitchell LM, Zhang L, Hourcade DE. Kemper C, et al. Among authors: mitchell lm. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):9023-8. doi: 10.1073/pnas.0801015105. Epub 2008 Jun 25. Proc Natl Acad Sci U S A. 2008. PMID: 18579773 Free PMC article.

10

Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.

Pham CT, Mitchell LM, Huang JL, Lubniewski CM, Schall OF, Killgore JK, Pan D, Wickline SA, Lanza GM, Hourcade DE. Pham CT, et al. Among authors: mitchell lm. J Biol Chem. 2011 Jan 7;286(1):123-30. doi: 10.1074/jbc.M110.180760. Epub 2010 Nov 3. J Biol Chem. 2011. PMID: 21047788 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters